|
EP2081929B1
(en)
|
2006-11-08 |
2013-01-09 |
Neurocrine Biosciences, Inc. |
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
|
|
CA2972242A1
(en)
|
2008-09-18 |
2010-04-22 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EP3351247A1
(en)
*
|
2010-06-01 |
2018-07-25 |
Auspex Pharmaceutical, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
EP4345100A3
(en)
|
2012-09-18 |
2024-04-10 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
JP2016506957A
(ja)
*
|
2013-01-31 |
2016-03-07 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｖｍａｔ２のベンゾキノロン阻害剤
|
|
WO2015048370A1
(en)
*
|
2013-09-27 |
2015-04-02 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2015084622A1
(en)
*
|
2013-12-03 |
2015-06-11 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
EP3398602A1
(en)
*
|
2014-01-27 |
2018-11-07 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
KR20160117596A
(ko)
|
2014-02-07 |
2016-10-10 |
오스펙스 파마슈티칼스, 인코포레이티드 |
신규 제약 제제
|
|
CN106061506A
(zh)
*
|
2014-02-07 |
2016-10-26 |
纽罗克里生物科学有限公司 |
包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
|
|
EP3105218B1
(en)
|
2014-02-13 |
2019-09-25 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
NZ725826A
(en)
*
|
2014-05-06 |
2023-05-26 |
Neurocrine Biosciences Inc |
Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
|
|
US9714246B2
(en)
*
|
2015-02-06 |
2017-07-25 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
AU2016229949B2
(en)
|
2015-03-06 |
2021-04-08 |
Auspex Pharmaceuticals Llc |
Methods for the treatment of abnormal involuntary movement disorders
|
|
EP3277689B1
(en)
|
2015-04-03 |
2019-09-04 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
KR20240125709A
(ko)
|
2015-06-23 |
2024-08-19 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
|
|
MY189367A
(en)
|
2015-08-12 |
2022-02-08 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
MX383906B
(es)
|
2015-10-09 |
2025-03-14 |
Teva Pharmaceuticals Int Gmbh |
Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
|
|
RS61645B1
(sr)
*
|
2015-10-30 |
2021-04-29 |
Neurocrine Biosciences Inc |
Valbenazin ditozilat i njihovi polimorfi
|
|
JP6869988B2
(ja)
*
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
|
|
WO2017182916A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Lupin Limited |
Novel process for preparation of tetrabenazine and deutetrabenazine
|
|
US10442800B2
(en)
*
|
2016-06-29 |
2019-10-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of NBI-98854, preparation method and use thereof
|
|
WO2018067945A1
(en)
|
2016-10-06 |
2018-04-12 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
WO2018102673A1
(en)
|
2016-12-02 |
2018-06-07 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
US10703750B2
(en)
|
2017-01-10 |
2020-07-07 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
CA3051830A1
(en)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
EP3585787A1
(en)
|
2017-02-27 |
2020-01-01 |
Sandoz AG |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
PE20191819A1
(es)
|
2017-03-15 |
2019-12-27 |
Auspex Pharmaceuticals Inc |
Analogos de deutetrabenazina, su preparacion y uso
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
AU2018241940B2
(en)
*
|
2017-04-01 |
2023-09-28 |
Adeptio Pharmaceuticals Limited |
Dihydrotetrabenazine for use in the treatment a movement disorder
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
SG11202004165UA
(en)
*
|
2017-11-08 |
2020-06-29 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
AU2018371771B2
(en)
|
2017-11-22 |
2024-06-20 |
Assia Chemical Industries Ltd |
Solid state form of Valbenazine
|
|
JP7212958B2
(ja)
|
2017-12-26 |
2023-01-26 |
▲蘇▼州科睿思制▲葯▼有限公司 |
バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
AU2019287524A1
(en)
*
|
2018-06-14 |
2020-12-24 |
Neurocrine Biosciences, Inc. |
VMAT2 inhibitor compounds, compositions, and methods relating thereto
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
US12565495B2
(en)
*
|
2019-08-12 |
2026-03-03 |
Luye Innomind Pharma Shijiazhuang Co., Ltd. |
VMAT2 inhibitor and preparation method therefor and application thereof
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CA3150961A1
(en)
|
2019-09-13 |
2021-03-18 |
John Tucker |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
AU2022241988A1
(en)
|
2021-03-22 |
2023-10-12 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|
|
EP4330255A1
(en)
|
2021-04-26 |
2024-03-06 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
BR112023026160A2
(pt)
|
2021-06-30 |
2024-03-05 |
Neurocrine Biosciences Inc |
Valbenazina para uso no tratamento de discinesia devido à paralisia cerebral
|
|
CA3220946A1
(en)
|
2021-06-30 |
2023-01-05 |
Angel S. Angelov |
Valbenazine for use in the add-on treatment of schizophrenia
|
|
EP4489754A1
(en)
|
2022-03-07 |
2025-01-15 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
IL319670A
(en)
|
2022-09-21 |
2025-05-01 |
Neurocrine Biosciences Inc |
VMAT2 inhibitors based on hexahydro-2H-pyridyl-1,2-[A]isoquinoline and methods of use
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|
|
WO2026050236A1
(en)
|
2024-08-27 |
2026-03-05 |
Neurocrine Biosciences, Inc. |
Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
|